| 
					Low-dose Interferon-alfa Does Not Improve Outcomes of Patients with Renal Cell ... - Cancer Consultants			 | 
						
		 		 | 
		
				
		 		 | 
		
					
| 
Cancer ConsultantsUpfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and ...  
 |